Literature DB >> 26318189

Frequent occurrence of oxacillin-susceptible mecA-positive Staphylococcus aureus (OS-MRSA) strains in two African countries.

Teresa Conceição1, Céline Coelho1, Hermínia de Lencastre2, Marta Aires-de-Sousa3.   

Abstract

BACKGROUND: Oxacillin-susceptible mecA-positive Staphylococcus aureus (OS-MRSA) isolates have been increasingly reported worldwide, but data regarding the African continent have not been available.
METHODS: Between 2010 and 2014, 1462 inpatients and healthcare workers were screened for MRSA nasal carriage in São Tomé and Príncipe (STP) and Angola, two Portuguese-speaking African countries (PALOP countries). We determined the presence of the mecA gene and the antimicrobial susceptibility profiles of the isolates. OS-MRSA clonal lineages were identified as well as the presence of virulence determinants, including Panton-Valentine leucocidin (PVL).
RESULTS: Out of 164 S. aureus hospital isolates tested, 29 (17.7%) were mecA positive, but susceptible to oxacillin, showing oxacillin MICs ≤3 mg/L. All OS-MRSA isolates were resistant to cefoxitin and most of them were also resistant to at least two antimicrobials other than β-lactams. The 29 OS-MRSA were distributed into two major clonal lineages: (i) PFGE type B-ST88-SCCmec IVa, associated with spa types t186/t325/t786/t1814/t1951, detected in Angola (n = 5) and STP (n = 10); and (ii) PFGE type C-t451/t648-ST8-SCCmec V, exclusively found in STP (n = 9). OS-MRSA showed at least two virulence determinants. PVL was detected in an isolate recovered in STP.
CONCLUSIONS: We describe a high prevalence of OS-MRSA among S. aureus strains recovered in two African countries. OS-MRSA in PALOP countries were mainly associated with ST88 and ST8, two prevalent MRSA clonal types in these countries. If direct testing for mecA is not available, cefoxitin susceptibility testing is highly recommended to avoid the misidentification of OS-MRSA.
© The Author 2015. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26318189     DOI: 10.1093/jac/dkv261

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  12 in total

1.  Heterogeneous oxacillin-resistant phenotypes and production of PBP2A by oxacillin-susceptible/mecA-positive MRSA strains from Africa.

Authors:  Marilyn Chung; Choon Keun Kim; Teresa Conceição; Marta Aires-De-Sousa; Hermínia De Lencastre; Alexander Tomasz
Journal:  J Antimicrob Chemother       Date:  2016-06-07       Impact factor: 5.790

2.  Molecular epidemiology of Staphylococcus aureus from Lambaréné, Gabon.

Authors:  K V Okuda; N Toepfner; A S Alabi; B Arnold; S Bélard; U Falke; L Menschner; S Monecke; A Ruppelt-Lorz; R Berner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-08-23       Impact factor: 5.103

3.  Whole-genome analysis uncovers loss of blaZ associated with carriage isolates belonging to methicillin-resistant Staphylococcus aureus (MRSA) clone ST5-VI in Cape Verde.

Authors:  Magdalena Wysocka; Tamar Monteiro; Carine de Pina; Deisy Gonçalves; Sandrine de Pina; Antonio Ludgero-Correia; Joao Moreno; Roxana Zamudio; Nada Almebairik; Laura J Gray; Manish Pareek; David R Jenkins; Marta Aires-de-Sousa; Herminia De Lencastre; Sandra Beleza; Isabel I Araujo; Teresa Conceição; Marco R Oggioni
Journal:  J Glob Antimicrob Resist       Date:  2021-05-27       Impact factor: 4.035

4.  Specific staphylococcal cassette chromosome mec (SCCmec) types and clonal complexes are associated with low-level amoxicillin/clavulanic acid and cefalotin resistance in methicillin-resistant Staphylococcus pseudintermedius.

Authors:  Alice Wegener; Peter Damborg; Luca Guardabassi; Arshnee Moodley; Lapo Mughini-Gras; Birgitta Duim; Jaap A Wagenaar; Els M Broens
Journal:  J Antimicrob Chemother       Date:  2020-03-01       Impact factor: 5.758

Review 5.  Staphylococcus aureus Toxins and Diabetic Foot Ulcers: Role in Pathogenesis and Interest in Diagnosis.

Authors:  Catherine Dunyach-Remy; Christelle Ngba Essebe; Albert Sotto; Jean-Philippe Lavigne
Journal:  Toxins (Basel)       Date:  2016-07-07       Impact factor: 4.546

6.  Prevalence and Characterization of Oxacillin Susceptible mecA-Positive Clinical Isolates of Staphylococcus aureus Causing Bovine Mastitis in India.

Authors:  Hiral Mistry; Paresh Sharma; Sudipta Mahato; R Saravanan; P Anand Kumar; Vasundhra Bhandari
Journal:  PLoS One       Date:  2016-09-07       Impact factor: 3.240

7.  Dissemination Of t437-SCCmecIV And Coagulase-Negative t037-SCCmecIII Types Among Borderline Oxacillin-Resistant Staphylococcus aureus Isolated From Skin Infections And Diabetic Foot Ulcers.

Authors:  Maria Stańkowska; Katarzyna Garbacz; Lidia Piechowicz; Marek Bronk
Journal:  Infect Drug Resist       Date:  2019-10-10       Impact factor: 4.003

8.  Identification and characterization of mutations responsible for the β-lactam resistance in oxacillin-susceptible mecA-positive Staphylococcus aureus.

Authors:  Tanit Boonsiri; Shinya Watanabe; Xin-Ee Tan; Kanate Thitiananpakorn; Ryu Narimatsu; Kosuke Sasaki; Remi Takenouchi; Yusuke Sato'o; Yoshifumi Aiba; Kotaro Kiga; Teppei Sasahara; Yusuke Taki; Feng-Yu Li; Yuancheng Zhang; Aa Haeruman Azam; Tomofumi Kawaguchi; Longzhu Cui
Journal:  Sci Rep       Date:  2020-10-09       Impact factor: 4.379

9.  First Report of Oxacillin Susceptible mecA-Positive Staphylococcus aureus in a Children's Hospital in Kunming, China.

Authors:  Mingbiao Ma; Minjun Chu; Lvyan Tao; Jue Li; Xiaojuan Li; Hailin Huang; Kexuan Qu; Haiping Wang; Li Li; Tingyi Du
Journal:  Infect Drug Resist       Date:  2021-07-06       Impact factor: 4.003

10.  Epidemiology of Staphylococcus aureus in neonates on admission to a Chinese neonatal intensive care unit.

Authors:  Wenjing Geng; Yujie Qi; Wenting Li; Thomas H McConville; Alexandra Hill-Ricciuti; Emily C Grohs; Lisa Saiman; Anne-Catrin Uhlemann
Journal:  PLoS One       Date:  2020-02-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.